This post was originally published on this site
https://i-invdn-com.akamaized.net/news/LYNXNPEC0Q1B5_M.jpg
Orbimed Advisors’s holding in 89bio, Inc. decreased to about 1.9 million shares with the transaction.
Orbimed Advisors first bought 89bio, Inc. stock in the fourth quarter of 2019. Orbimed Advisors also owns Alexion Pharmaceuticals Inc (NASDAQ:ALXN), Biogen Inc (NASDAQ:BIIB), Neurocrine Biosciences Inc (NASDAQ:NBIX) and Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX). 89bio, Inc. is its number twelve position by number of shares and market value among pharmaceuticals stocks.
In contrast, Millennium Management and Point72 Asset Management established new holdings in 89bio, Inc.
